Elektrofi Announces Oversubscribed $112.25 Million Series C Financing to Establish Commercial-Scale GMP Manufacturing Capacity & Accelerate Clinical Development Across its Growing Portfolio of Partnered Programs• Financing led by Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations, with participation from 16 additional new and existing investors.

Elektrofi宣布超额认购11225万美元的C系列融资，以建立商业规模的GMP生产能力，并通过其不断增长的合作项目组合加速临床开发•由Novo Holdings，RA Capital Management，Royalty Pharma，SR One和TPG Life Sciences Innovations牵头的融资，另有16名新投资者和现有投资者参与。

• Proceeds will be used, in part, to establish Ph3 and commercial-scale GMP manufacturing capacity that will accelerate clinical development and provide global support for a growing portfolio of programs with existing and emerging partnersBOSTON, October 31, 2024-- Elektrofi, Inc., a biopharmaceutical delivery technology company focused on improving the patient experience and expanding access to life-changing medicines through the freedom of self-administration, today announced the closing of an upsized and oversubscribed $112.25M Series C financing.

•收益将部分用于建立Ph3和商业规模GMP生产能力，这将加速临床开发，并为与现有和新兴合作伙伴合作的不断增长的项目组合提供全球支持。2024年10月31日，波士顿——Elektrofi，Inc.，一家专注于通过自我管理的自由来改善患者体验和扩大改变生命的药物的获取的生物制药递送技术公司，今天宣布关闭一项规模较大且超额认购的11225万美元C系列融资。

The financing was co-led by Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations, with participation from Eli Lilly and Company. Other premier new and existing life sciences investors participated, including Braidwell LP, BVF, Catalio Capital Management, Checkpoint Capital, Deep Track Capital, General Catalyst, Janus Henderson Investors, Kearny Venture Partners, Logos Capital, Marshall Wace, Paradigm BioCapital, Samsara Biocapital, Woodline Partners LP, and an investment fund associated with Leerink Partners..

此次融资由Novo Holdings、RA Capital Management、Royalty Pharma、SR One和TPG Life Sciences Innovations共同牵头，礼来公司（Eli Lilly and Company）参与。其他主要的新的和现有的生命科学投资者参加了会议，包括Braidwell LP、BVF、Catalio Capital Management、Checkpoint Capital、Deep Track Capital、General Catalyst、Janus Henderson investors、Kearny Venture Partners、Logos Capital、Marshall Wace、Paradigm BioCapital、Samsara BioCapital、Woodline Partners LP以及与Leerink Partners相关的投资基金。

Proceeds from the financing will support the establishment of Ph3 and commercial-scale GMP manufacturing lines. The addition of this capacity to the Company's first GMP line, which is expected to be operational for clinical manufacturing in early 2025, will enable current and future programs to move quickly from inception to launch..

融资收益将支持建立Ph3和商业规模GMP生产线。该公司的第一条GMP生产线预计将于2025年初投入临床生产，增加这一能力将使当前和未来的计划从开始到启动迅速发展。

'At Elektrofi, we envision a world in which patients have the independence they need – around how and where they take their medications – to live life on their terms,' said Chase Coffman, CEO. 'The industry is on the cusp of a drug delivery revolution, and Elektrofi is proud to be leading it with Hypercon™, a broadly applicable platform for the hyper concentration and stabilization of biopharmaceuticals.

首席执行官蔡斯·科夫曼（ChaseCoffman）说：“在Elektrofi，我们设想的世界是，患者拥有所需的独立性，即如何以及在哪里服用药物，以按照自己的条件生活。”该行业正处于药物输送革命的尖端，Elektrofi很自豪能够凭借Hypercon™引领该行业，Hypercon™是一个广泛适用的生物制药超浓缩和稳定平台。

With our team of industry experts, distinguished Board Directors, world-class investors, and pharma partners, we look forward to scaling our proprietary technology in the interest of bringing life-changing medicines to patients across the globe as quickly as possible.'.

凭借我们的行业专家团队、杰出的董事会成员、世界级的投资者和制药合作伙伴，我们期待着扩大我们的专有技术，以便尽快为全球患者带来改变生命的药物。”

About Elektrofi

关于Elektrofi

Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentrated microparticle technology platform, Hypercon™, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration.

Elektrofi是一家生物制药配方技术公司，通过让患者能够控制他们想要如何接受和受益于改变生命的药物，正在彻底改变生物疗法的交付。我们突破性的超浓缩微粒技术平台Hypercon™通过方便的家庭皮下自我给药，解决了与静脉注射生物疗法相关的局限性。

With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally..

我们专注于单克隆抗体，治疗性蛋白质和其他大分子药物，与战略合作伙伴合作创建，开发和商业化皮下生物疗法。我们相信，以患者为中心的医疗保健方法可以带来一个更健康的世界。我们的总部位于波士顿，在全球范围内进行创新。

Formulating the Future of Biologics™ www.Elektrofi.comContact:

制定Biologics™的未来www.Elektrofi.com联系方式：

Elektrofi Media Inquiries: media@elektrofi.com

媒体咨询Electrofi：media@elektrofi.com